Global Bone Densitometer Devices Market value is estimated to reach US$ 335.7 Mn in 2022 and is expected to reach US$ 501.4 Mn by the year 2032 end | Data analysis by FMI

Prevalence of Osteoporosis and Vitamin D deficiency Building Market – Ageing Remains Primary Catalyst

Driven primarily by rising incidences of osteoporosis and other bone-related disorders, the market will also be fuelled by the ensuing awareness about growing osteoporosis incidences. Increased emphasis on preventive healthcare, early diagnosis, and quality treatment are identified to be among the key factors spurring the demand for bone densitometer devices globally. Ageing, resulting in almost threefold risks of acquiring wrist, hip, and vertebral osteoporosis, will remain a major market growth catalyst.

Moreover, increasing prevalence of vitamin D and calcium deficiency disorders will also escalate the demand in near future. Burgeoning cancer prevalence is boosting the number of patients undergoing chemotherapy, which is further identified to affect their bone density in the long run. This will be another driver to growth of bone densitometer market. Evidently increasing integration of DXA into routine health check-ups will also escalate market growth over the forecast period.

Developed Markets Marching Ahead, Asian Countries to Witness Robust Growth

North America will continue to represent the largest market for bone densitometer devices, followed by Western Europe and Asia Pacific. Latin America and MEA will witness relatively lower growth rates.

• The U.S. will continue to dominate North American market with nearly 75% revenue share of the region and by 2026, North America is expected to surpass a value of US$ 204 Mn, grabbing over half of the market revenue share.
• APEJ will be the most lucrative, fastest growing market for bone densitometer devices. Led by China, followed by India and ANZ, this region will approach US$ 61 Mn in 2026, expanding at CAGR of 4.2% over 2016-2026. The Chinese market for bone densitometer devices is expected to exceed US$ 20 Mn in revenues, whereas India’s revenues are estimated at over US$ 17 Mn by 2026 end.

Request for Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-733

Product-wise Segmentation

By product, the global consumption of axial bone densitometer will possibly account for the revenues of US$ 272.3 Mn in 2026. This segment will grow at an estimated 3.7% of CAGR, gaining over 150 BPS during 2016-2026 against peripheral bone densitometer segment. Axial bone densitometer devices will continue to gain higher traction due to superior accuracy and precision, accounting for around 70% value share by 2026. Peripheral bone densitometer segment is also likely to witness steady adoption, as it allows short scan time and lesser exposure to radiation.

Technology-wise Segmentation

Based on technology, dual energy X-ray absorptiometry (DXA) segment is expected to remain dominant with nearly 65% share by 2026 end. This segment will possibly attain a value worth US$ 253 Mn in 2026, expanding at the highest CAGR of 3.7%. Quantitative ultrasound (QUS) segment is anticipated to register a 3.2% of CAGR, reaching over US$ 88 Mn by 2026 end.

End-user-wise Segmentation

In terms of end-user, hospitals segment will remain the largest consumer of bone densitometer devices, accounting for revenues worth US$ 252.3 Mn in 2026. Diagnostic centres, the second largest end-user segment with an estimated value of around US$ 80 Mn by 2026, is expected to witness the highest CAGR of 3.8% over the forecast period. Hospitals are likely to capture around 65% share in 2026, whereas diagnostic centres will bag over 20% share in 2026 market revenues.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-733

Beetling Trends and Upcoming Opportunities Fostering Demand for Bone Densitometer Devices

Increasing adoption of DXA, coupled with growing prominence of ultrasound technology, will be important trends in market. Improving healthcare infrastructure and extended reimbursement for osteoporosis treatment are also highlighted as influential trends. While flourishing medical tourism initiatives will remain a growing trend, strategic M&A activities will continue to trend among key players.

Manufacturers are likely to witness several untapped opportunities in developing Asian markets, which are primarily driven by exploding population and immense healthcare burden. Governments are also increasingly supporting the market through favourable bone density measurement awareness programs.